FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market Opportunity in Rare Autoimmune Segment | DelveInsight

DelveInsight Business Research, LLP United States of America United Kingdom

[phone]

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fda-approval-of-amgens-uplizna-for-igg4-related-disease-opens-new-market-opportunity-in-rare-autoimmune-segment--delveinsight-302427347.html